checkAd
    Startseite > Aktien > Genmab > Nachrichten
    Genmab Aktie
    28,55
     
    USD
    -0,66 %
    -0,19 USD
    Letzter Kurs 02:00:00 Nasdaq
    28,53
     
    USD
    200 STK
    Geldkurs 06.06.24
    28,55
     
    USD
    6.400 STK
    Briefkurs 06.06.24
    ISIN: US3723032062 · WKN: A1WZYB · SYM: GMAB · Dänemark

    Neueste Nachrichten

    Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    03.06.24 · Business Wire (engl.) · Genmab
    Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
    02.06.24 · Business Wire (engl.) · Genmab
    Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
    01.06.24 · Business Wire (engl.) · Genmab
    Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
    23.05.24 · Business Wire (engl.) · Genmab
    Genmab Completes Acquisition of ProfoundBio
    21.05.24 · Business Wire (engl.) · Genmab
    Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
    14.05.24 · Business Wire (engl.) · Genmab
    TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
    30.04.24 · Business Wire (engl.) · Pfizer
    FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer
    30.04.24 · Business Wire (engl.) · Pfizer
    Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
    03.04.24 · Business Wire (engl.) · Genmab
    U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
    27.02.24 · Business Wire (engl.) · Genmab
    Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
    02.02.24 · Business Wire (engl.) · Pfizer
    TIVDAK Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
    09.01.24 · Business Wire (engl.) · Pfizer